Abstract
This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy and tolerability, drug interactions, and dosing and administration of cobicistat. Searches of MEDLINE and International Pharmaceutical Abstracts from 1964 to February 2015 were conducted using the search terms cobicistat and GS-9350. Relevant information was extracted from the identified clinical trials and review articles. Abstracts from the Conference on Retroviruses and Opportunistic Infections (2014-2015) and the Interscience Conference on Antimicrobial Agents and Chemotherapy (2013-2014) were also searched. Cobicistat is a PK enhancer lacking antiviral activity that, via selective cytochrome P-450 (CYP) 3A inhibition, inhibits the metabolism of certain antiretroviral medications and is used for prolonging their effect. Cobicistat has been studied as a booster of elvitegravir, a second-generation integrase inhibitor, and of the protease inhibitors atazanavir and darunavir. Data on its clinical efficacy and tolerability have been presented in 2 Phase II trials and in 9 Phase III trials, which reported durable efficacy in terms of achievement of sustained suppression of HIV-1 RNA levels to <50 copies/mL for a...Continue Reading
References
Jul 7, 2007·Critical Reviews in Toxicology·Yasuhiro Masubuchi, Toshiharu Horie
Jan 1, 2010·Clinical Pharmacology and Therapeutics·A A MathiasB P Kearney
Aug 5, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Polina GermanBrian P Kearney
Mar 18, 2011·AIDS·Calvin CohenBrian P Kearney
Aug 4, 2011·AIDS·Richard ElionUNKNOWN GS-US-216-0105 Study Team
Jun 27, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Polina GermanAnita Mathias
Jul 4, 2012·Lancet·Edwin DeJesusUNKNOWN GS-236-0103 Study Team
Jul 4, 2012·Lancet·Paul E SaxUNKNOWN GS-US-236-0102 study team
Aug 2, 2012·Antimicrobial Agents and Chemotherapy·Eve-Irene LepistAdrian S Ray
Jun 19, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Srinivasan RamanathanBrian P Kearney
Sep 17, 2013·ClinicoEconomics and Outcomes Research : CEOR·Timothy JudayTanya Bentley
Feb 20, 2014·Antimicrobial Agents and Chemotherapy·Joseph M CustodioSrinivasan Ramanathan
Mar 13, 2014·Journal of Clinical Pharmacology·Mari ShiomiShin Irie
Apr 2, 2014·Antimicrobial Agents and Chemotherapy·Tong ZhuRobert S Wallis
Apr 9, 2014·HIV Clinical Trials·A MillsJ Szwarcberg
Aug 12, 2010·ACS Medicinal Chemistry Letters·Lianhong XuManoj C Desai
Jun 9, 2014·The Lancet Infectious Diseases·Anton PozniakBill Guyer
Jul 16, 2014·Antimicrobial Agents and Chemotherapy·William WeissRichard Vickers
Sep 4, 2014·Antimicrobial Agents and Chemotherapy·Mariana CastanheiraRonald N Jones
Oct 29, 2014·HIV Clinical Trials·Rima KulkarniKirsten L White
Dec 1, 2014·HIV Clinical Trials·Cheryl K McDonaldJavier Szwarcberg
Citations
Dec 17, 2015·European Journal of Endocrinology·Matthias KroissSilviu Sbiera
May 18, 2016·Reviews in Medical Virology·Stephanie PfaenderEike Steinmann
Nov 1, 2016·Expert Opinion on Pharmacotherapy·Nathan R UngerLindsey M Childs-Kean
Jun 2, 2017·Cell Death & Disease·Mayilaadumveettil NishanaSathees C Raghavan
May 31, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Mohamed G AttaGregory M Lucas
Sep 2, 2017·The Journal of Pharmacology and Experimental Therapeutics·Rachel A Murphy, Monica A Valentovic
Nov 2, 2019·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoGiuliano Rizzardini
Feb 26, 2016·AIDS·Stein SchalkwijkUNKNOWN PANNA network
Oct 14, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul E SaxJohn R Koethe
Jan 9, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Dario Cattaneo, Cristina Gervasoni
Apr 14, 2017·The Journal of Antimicrobial Chemotherapy·Emilie R ElliotMarta Boffito
Aug 19, 2017·Scientific Reports·Carlos J ChaccourJosé Luis Del Pozo
Oct 29, 2020·Archives of Toxicology·Jukka HakkolaOlavi Pelkonen
Feb 12, 2021·AIDS Research and Human Retroviruses·Lawrence D YorkLori E Fantry
Feb 24, 2021·AIDS Research and Human Retroviruses·Jovana MilicGiovanni Guaraldi